Endocrinology Advisor6d
Belzutifan Gets Priority Review for Advanced Pheochromocytoma and Paraganglioma
The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.
Cure Today5d
FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Nature3y
The first FDA approved treatment for ultra-rare endocrine tumors
However, between 15 and 20% of patients are diagnosed after they have already progressed to late-stage metastatic disease ... certain mutations may render advanced PPGL particularly vulnerable ...
Contract Pharma7d
Merck’s WELIREG Accepted for Priority Review by FDA for Pheochromocytoma and Paraganglioma
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Pharm Exec7d
FDA Grants Priority Review to Merck’s Welireg for Advanced, Unresectable, or Metastatic Pheochromocytoma, Paraganglioma
Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...